Skip to main content

Governments given deadline to increase testing and treatment

War in Gaza:: find out how we're responding
Learn more

Ahead of the first-ever Global Ministerial Conference on ‘Ending TB’ in Moscow, Médecins Sans Frontières (MSF) and the Stop TB Partnership called for countries with high burdens of tuberculosis (TB) to implement the latest international treatment and testing standards by World TB Day, 24 March 2018.

TB remains the world’s top infectious disease killer, with 1.7 million deaths in 2016. According to the latest World Health Organization (WHO) Global TB report, progress in diagnosing and treating all forms of TB is stalling in most countries. More than 4.1 million people with TB remained undiagnosed or unreported in 2016, and only one in five people with multidrug-resistant (MDR–TB) was started on treatment. Of those people, just over half were cured.

“Why do we continue to remain out of step when it comes to testing people for TB, when it’s the critical first step to treating this curable disease and preventing its spread?” said Dr Francis Varaine, TB Medical Advisor at MSF.

Governments urgently need to step up, to stop people from needlessly dying of TB. Dr Francis Varaine, TB Medical Advisor at MSF

According to a survey in the third edition of Out of Step, a joint report by MSF and the Stop TB Partnership that reviews TB policies and practices in 29 countries – which account for nearly three-quarters of the global TB burden – 40 per cent of people with TB remain undiagnosed.

Only seven of the countries have made Xpert MTB/RIF, a rapid molecular test, widely available for diagnosing TBArmenia, Belarus, Brazil, Georgia, South Africa, Swaziland, and Zimbabwe. Newer medicines and regimens for treating drug-resistant (DR-TB) have demonstrated better outcomes than today’s standard regimens, which cure just half of people with MDR-TB and only 28 per cent of people with the even more deadly extensively drug-resistant (XDR-TB). Seventy-nine per cent of countries surveyed include the newer drug bedaquiline in their national guidelines, and 62 per cent include delamanidWHO will carry out a review of emerging evidence on the use of delamanid in early 2018.. Yet globally in 2016, these drugs were made available to less than five per cent of people who could have benefitted from them.

This week, MSF and the Stop TB partnership released the report Out of Step in Eastern Europe and Central Asia (EECA), presenting the results of an eight-country survey of national TB policies and practicesArmenia, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Russian Federation, Tajikistan and Ukraine.

Among the countries surveyed, 75 per cent have adopted a policy to use rapid molecular testing instead of older, slower testing methods, yet only half of those countries are actually using the test widely. An estimated 46,000 people with DR-TB in the EECA region went undiagnosed in 2015.

MSF TB Treatment in Mumbai, India

“Despite its deadly toll, most countries lag behind in implementing the existing and new tools that are available to tackle TB,” said Lucica Ditiu, Executive Director of the Stop TB Partnership.

“The WHO Global Ministerial Conference is the first step for concrete, bold and measurable commitments by ministers of health towards a strong accountability framework for heads of state and governments during the UN High Level meeting on TB.”

At the Global Ministerial Conference this week, Mariam Avanesova, who was treated for MDR-TB in Armenia in 2010-2012 and represents TBpeople, the Eurasian network of people with TB experience, will hand over a petition to WHO’s Director-General, Dr Tedros Ghebreyesus.

The #StepUpforTB petition is an urgent call for health ministers in key TB-affected countries to get their TB policies and practices in line with international standards, as defined by WHO, including testing and treatment of TB and its drug-resistant forms. Initiated by MSF and the Stop TB partnership, the petition has been signed by more than 30,000 people from around the world united with people affected by TB.

“After being cured of MDR-TB, I decided to continue working in this area because I find it unacceptable that people are dying because either their diagnosis was too late and the drugs didn't work, or they simply quit because the side effects from 20 tablets a day for two years were too much,” said Avanesova.  

“I really want to appeal to all governments to step up to make timely TB testing and treatment accessible to all people who need it. Urgent action on the ground is what I'm hoping to see come out of this conference.”

MSF has been treating people with TB for 30 years. In 2016, MSF treated more than 20,000 people with TB, including 2,700 people with multi drug-resistant TB (MDR-TB).